Accumulating evidence to date indicates that interactions between circulating aPL and cell surface molecules of target cells such as endothelial cells and trophoblasts underlie the clinical disorders in APS [1,4]. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.